Pneumococcal Vaccine Market Report 2026

The pneumococcal vaccine market size has grown strongly in recent years. It will grow from $9.4 billion in 2025 to $9.94 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to high childhood pneumonia burden, inclusion in national immunization programs, strong support from global health organizations, rising awareness of invasive pneumococcal disease, proven efficacy of pcv vaccines.

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $12.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to launch of next-generation pcv vaccines, expanding adult vaccination recommendations, growth in healthcare access in emerging economies, increasing antimicrobial resistance concerns, government funding for preventive immunization. Major trends in the forecast period include expansion of conjugate vaccines for broader serotype coverage, increased focus on pediatric and geriatric immunization programs, rising adoption of combination and booster vaccination strategies, strengthening public-private partnerships for immunization coverage, growth in preventive healthcare and national immunization schedules.

The rising prevalence of pneumococcal infections is expected to drive the growth of the pneumococcal vaccine market in the coming years. Pneumococcal infection refers to illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus, including conditions such as pneumonia, bloodstream infections, ear infections, and sinus infections. Pneumococcal vaccines work by stimulating the immune system to produce antibodies against pneumococcal bacteria, helping to reduce or eliminate disease-causing bacteria and toxins and protecting vulnerable populations such as children, older adults, and individuals with weakened immune systems from various pneumococcal diseases. For instance, in July 2025, according to the Immunisation Coalition, an Australia-based independent not-for-profit organization, reported cases of invasive pneumococcal disease (IPD) increased consistently over recent years, rising from 1,869 cases in 2022 to 2,265 in 2023 and reaching 2,379 cases in 2024. Therefore, the growing prevalence of pneumococcal infections is contributing to the expansion of the pneumococcal vaccine market.

Leading companies operating in the pneumococcal vaccine market are focusing on product innovation to enhance their market position and profitability. For example, in July 2023, Merck & Co. Inc., a US-based pharmaceutical company, introduced the V116 vaccine. V116 is designed to target eight specific serotypes of Streptococcus pneumoniae that are mainly responsible for pneumococcal disease in adults. Compared with existing pneumococcal vaccines, V116 has demonstrated improved immunogenicity across multiple serotypes in adult populations and has shown positive immune responses in both vaccine-naïve individuals and those previously vaccinated. The U.S. Food and Drug Administration has granted V116 breakthrough therapy designation, and the vaccine is currently undergoing Phase 3 clinical development.

In December 2024, Sanofi SA, a France-based pharmaceutical company, expanded its collaboration with SK Bioscience Co. Ltd. to further advance the development of its licensed pneumococcal conjugate vaccine. Through this expanded partnership, Sanofi aims to accelerate late-stage development and strengthen its pneumococcal vaccine portfolio by leveraging SK Bioscience’s advanced expertise in vaccine development and manufacturing. SK Bioscience Co. Ltd. is a South Korea-based biotechnology company specializing in pneumococcal vaccine research, development, and biomanufacturing.

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE.

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pneumococcal vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pneumococcal vaccine market by increasing the cost of imported biologics, active ingredients, and cold-chain packaging materials, thereby impacting overall vaccine pricing and procurement budgets. The effects are most visible in conjugate vaccine segments and in regions reliant on imports such as parts of asia-pacific, latin america, and africa. Public immunization programs face budgetary pressure, while manufacturers experience margin constraints. However, tariffs have also encouraged local manufacturing, technology transfer, and regional production hubs, supporting long-term supply resilience and self-sufficiency.

The pneumococcal vaccine market research report is one of a series of new reports that provides pneumococcal vaccine market statistics, including pneumococcal vaccine industry global market size, regional shares, competitors with a pneumococcal vaccine market share, detailed pneumococcal vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pneumococcal vaccine industry. This pneumococcal vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pneumococcal vaccine is an immunization that provides protection against serious and potentially life-threatening pneumococcal infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, and sepsis. It is highly effective in safeguarding infants against one of the leading causes of meningitis and other illnesses, such as acute ear infections.

The primary pneumococcal vaccines include Prevnar 13, Synflorix, Pneumovax 23, and others. Prevnar 13 is a pneumococcal conjugate vaccine that contains 13 different strains of Streptococcus pneumoniae and is used in children as well as tested in immunocompromised patients to prevent pneumococcal disease. These vaccines are administered through routes such as intravenous, intramuscular, and subcutaneous injection and are distributed through pharmacies, community clinics, public health agencies, and other channels for use by pediatric and adult populations.

The pneumococcal vaccine market consists of sales of vaxneuvance, prevnar 20, pneumococcal conjugate vaccines (PCV)10, and pneumococcal conjugate vaccines (PCV)7. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.